Precision Biosciences (DTIL) Accumulated Depreciation & Amortization (2018 - 2025)
Precision Biosciences (DTIL) has disclosed Accumulated Depreciation & Amortization for 7 consecutive years, with $28.1 million as the latest value for Q4 2024.
- On a quarterly basis, Accumulated Depreciation & Amortization rose 10.15% to $28.1 million in Q4 2024 year-over-year; TTM through Dec 2024 was $28.1 million, a 10.15% increase, with the full-year FY2024 number at $28.1 million, up 10.15% from a year prior.
- Accumulated Depreciation & Amortization was $28.1 million for Q4 2024 at Precision Biosciences, up from $25.5 million in the prior quarter.
- In the past five years, Accumulated Depreciation & Amortization ranged from a high of $28.1 million in Q4 2024 to a low of $19.1 million in Q4 2020.
- A 5-year average of $23.7 million and a median of $23.9 million in 2021 define the central range for Accumulated Depreciation & Amortization.
- Peak YoY movement for Accumulated Depreciation & Amortization: soared 79.15% in 2020, then decreased 8.55% in 2022.
- Precision Biosciences' Accumulated Depreciation & Amortization stood at $19.1 million in 2020, then increased by 25.35% to $23.9 million in 2021, then dropped by 8.55% to $21.9 million in 2022, then rose by 16.55% to $25.5 million in 2023, then rose by 10.15% to $28.1 million in 2024.
- Per Business Quant, the three most recent readings for DTIL's Accumulated Depreciation & Amortization are $28.1 million (Q4 2024), $25.5 million (Q4 2023), and $21.9 million (Q4 2022).